Year: 2009
Type: editorial
Abstract: Tryptase is a mediator produced and secreted by mast cells. Both α- and pro-β-tryptase are secreted continuously, mature β-tryptase is stored in mast cell granules and released following mast cell activation, mostly during IgE-mediated allergic reactions, together with histamine, prostaglandins, leukotrienes and other mediators. The commercially available fluorescence immunoassay measures both α- and β-tryptase. The baseline serum level in the absence of an allergic or anaphylactic reaction is considered as an indicator of the whole body mast cell load and, if elevated, may indicate the presence of systemic mastocytosis. If the serum tryptase level increases significantly within 1–5 h after the first symptoms of a suspected systemic hypersensitivity reaction it confirms its mostly allergic, IgE-mediated origin [1]. In this issue, Potier et al. [2] have published an article on cutaneous manifestations during anaphylaxis caused by insect stings and their relation to a baseline serum tryptase (bT) over 13.5 ng/mL. Among 131 patients on venom immunotherapy for anaphylaxis due to Hymenoptera stings they found 14 (10.7%) with an elevated bT. In accordance with previous publications [1, 3, 4] they observed that patients with elevated bT had sustained significantly more severe, mostly cardiovascular anaphylactic sting reactions than those with normal bT. Interestingly they also noted a difference in skin symptoms in these patients compared with those without elevated bT. The latter had urticaria and angioedema more often, while those with elevated bT more often presented with flush as the dominant cutaneous symptom. No systemic cutaneous symptoms were observed in about a quarter of patients with elevated bT, but only in 9% of those with normal bT. Moreover patients with elevated bT had more often suffered repeated anaphylactic sting reactions. Because an elevated bT may be an indicator of systemic mastocytosis the authors also screened for systemic mastocytosis by skin and bone marrow biopsy in 19 of the 23 patients with elevated bT, and diagnosed mastocytosis in seven patients. Because not all patients with elevated bT had biopsies and minor criteria like c-kit mutation and co-expression of CD2/CD25 by kit+mast cells could not be analysed in this study, some cases of systemic mastocytosis may have been missed. We know from two recent large studies on a total of 320 cases of mastocytosis [5, 6] that these patients are at a highly increased risk to develop anaphylaxis, not only to Hymenoptera stings, but also to foods, drugs and other elicitors like alcohol, latex or exercise. Anaphylactic reactions were reported in 22–49% of adult individuals and in 6–9% of children with mastocytosis, while the lifetime prevalence of anaphylaxis in the whole population is estimated to be about 1% [7]. The association of an elevated bT with anaphylaxis has so far only been studied systematically for Hymenoptera stings, but not for other frequent causes of anaphylaxis like foods and drugs. The observation of anaphylaxis due to a Diptera sting in a patient with elevated bT in the study by Potier et al. [2] indicates that bT should be analysed systematically in patients with anaphylaxis, not only those due to frequent causes like venoms, foods or drugs. Several cases of fatal anaphylaxis due to Hymenoptera stings in patients with systemic mastocytosis have been described in the literature [7, 8]. How can we explain the differences in presentation of clinical symptoms between patients with an elevated bT with or without documented mastocytosis, and those with a normal bT: More flush, less urticaria and angioedema: It is well known that mastocytosis patients develop flush and itching to various stimuli besides allergens, like alcohol, exercise, change in temperature, pressure or emotional stress [5, 9, 10], which are obviously not IgE mediated. Besides the increased whole-body load of mastocytes and the consequently higher amount of mediators released, the altered morphology and possibly also production and release of mediators by these cells may attribute to this phenomenon. Mostly severe cardiovascular reactions: During an anaphylactic reaction in patients with an increased whole-body mast cell load very large amounts of mediators can be released, also from mast cells in cardiac tissue and arteries, especially coronary arteries, which are increased in number in patients with systemic mastocytosis, and most likely also in those with elevated bT but not documented mastocytosis [11]. This may be responsible for pharmacologically more threatening levels in the central vascular system including the heart resulting in predominantly cardiovascular symptoms. We observed a tryptase level of over 1000 ng/ml in a post-mortem serum sample from a mastocytosis patient who died from a wasp sting [7]. More frequent recurrent anaphylactic sting reactions in patients with elevated bT: Immunotherapy in patients with mastocytosis and those with an elevated bT may be delayed because of the often low and sometimes even absent vespid-specific serum IgE. Symptoms of non-IgE-induced mediator release could have occurred as a consequence of the effects of peptides like melittin and mast cell degranulating peptide from honeybee or mastoparan from Vespula venom. What can we learn from these observations? All patients with anaphylaxis – irrespective of the causing allergen – and also patients with recurrent flushing of unknown reason should be tested for baseline serum tryptase. If a level over 11.4 ng/mL (the new upper limit of normal serum concentration) is found, this is an indication that the patient could suffer from systemic mastocytosis. The skin should be examined carefully for alterations like urticaria pigmentosa or teleangiectasia macularis eruptiva perstans and – if found – a skin and bone marrow biopsy should be taken. If the bT level is over 20 ng/mL a bone marrow biopsy is indicated also in the absence of cutaneous alterations. Further investigations for minor criteria (c-kit mutation, co-expression of CD2/CD25 by kit+mast cells) may be helpful in unclear cases [10]. All patients with mastocytosis should receive an emergency kit including an adrenaline auto-injector (Epipen®, ALK-Abello, Horsholm, Denmark or AnaPen®, Lincoln Medical Ltd, Salisbury, UK) and tablets of a rapidly acting antihistamine (fexofenadine or l-cetirizine), and be instructed in the use of the kit. Furthermore they should be controlled regularly with regard to possible complications of mastocytosis like osteoporosis, gastro-intestinal problems like gastric ulcers or associated haematological disease, and further measures should be taken according to current international recommendations [10, 12]. Patients with only slightly elevated bT below 20 ng/mL, and no clinical symptoms should be controlled regularly for bT and clinical symptoms, and further measures should be taken (bone marrow biopsy, etc.) when bT increases over 20 ng/mL or clinical symptoms suspected of being due to mastocytosis arise. Patients with anaphylaxis and elevated bT with or without documented mastocytosis should be instructed carefully how to avoid further allergen exposure. Specific-allergen immunotherapy has been shown to be effective and usually safe in such patients with Hymenoptera venom allergy [4, 13–15]. Because three patients with Hymenoptera venom allergy and systemic mastocytosis died following restings after stopping venom immunotherapy [7, 8], venom immunotherapy for life is recommended in patients with mastocytosis.
Source: Clinical & Experimental Allergy
Author: U. R. Müller
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2029464419
